Skip to content

Evox to present new exosome engineering advances at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

Evox data demonstrates the targeting and enhanced delivery of engineered exosomes using its proprietary DeliverEX platform

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces today that the company will present data at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021.

Scientists will present results using Evox’s DeliverEXTM technology to engineer exosomes for  1) Improved loading and delivery of cytosolic enzymes, 2) Extended in vivo circulation in plasma, and 3) Antibody-directed targeting of exosomes in vivo to tissues of interest.

“ We are very pleased to present data at ASGCT which highlights some of the advances in our DeliverEXTM platform and their application to the development of exosome-based therapeutics. These proprietary exosome engineering advances represent cutting edge science and highlight our leading position in the development of next generation exosome therapeutics,” said Dr. Antonin de Fougerolles, Chief Executive Officer of Evox Therapeutics.

Poster Presentations #454 - Presented on Tuesday, May 11:

Albumin-Decorated Exosomes Demonstrate Extended Circulation Time In Vivo.

Poster Presentations #455 - Presented on Tuesday, May 11:

Using Novel Intein Technology to Deliver Exosome-Based Therapeutics.

Poster Presentations #686 - Presented on Tuesday, May 11:

Antibody Displaying Extracellular Vesicles (Fc-EVs) for Delivery of Tumor Targeted Therapeutics.

For enquiries, please contact:

Dr Antonin de Fougerolles, Chief Executive Officer, Evox Therapeutics Ltd +44 (0) 1865 819140

Simon Conway / Natalie Garland-Collins, FTI Consulting +44 (0) 203 727 1000

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Backed by Oxford Sciences Innovation and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.